IGC Pharma, Inc. (IGC)

0.5200 +0.0120 (+2.36%) 收市：04:00PM EDT

IGC Pharma, Inc.

10224 Falls Road
Potomac, MD 20854
United States
301 983 0998
https://igcpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 61

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Ram Mukunda	President, CEO & Director	705k	無	1959
Ms. Claudia Grimaldi	VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director	245k	無	1971
Mr. Rohit Goel	Senior Director of Accounting & Principal Accounting Officer	無	無	1994

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

公司管治

截至 無 止，IGC Pharma, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。